EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid

Anjali Negi, Summaya Perveen, Ria Gupta, Parvinder Pal Singh, Rashmi Sharma iD

Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2264-2286

DOI: 10.1021/acs.jmedchem.3c01892 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.02.2024. Verfasst von Anjali Negi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Nitroimidazoles, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Science and Engineering Research Board, University Grants Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis (anti-TB) treatment regimens and have emerged as potential solutions for combating drug-resistant TB. These drugs have proven to be effective in treating drug-resistant TB when used in combination. However, concerns have been raised about the eventual loss of these drugs due to evolving resistance mechanisms and certain adverse effects such as prolonged QT period, gastrointestinal problems, hepatotoxicity, and renal disorders. This Perspective emphasizes the properties of these first-in-class drugs, including their mechanism of action, pharmacokinetics/pharmacodynamics profiles, clinical studies, adverse events, and underlying resistance mechanisms. A brief coverage of efforts toward the generation of best-in-class leads in each class is also provided. The ongoing clinical trials of new combinations of these drugs are discussed, thus providing a better insight into the use of these drugs while designing an effective treatment regimen for resistant TB cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantNitroimidazolesDrug-Related Side Effects and Adverse ReactionsDiarylquinolinesHumansAntitubercular AgentsOxazolesDrug Resistance

Substanzen

bedaquilineOPC-67683Antitubercular AgentspretomanidNitroimidazolesOxazolesDiarylquinolines

Autor:innen und Institutionen

  • Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
  • Natural Products and Medicinal Chemistry, CSIR - Indian Institute of Integrative Medicine, Jammu-180001, India.

ORCID-Profile: Rashmi Sharma

Förderung

  • Council of Scientific and Industrial Research, India
  • Science and Engineering Research Board
  • University Grants Committee

Zitieren

APA

Negi, A., Perveen, S., Gupta, R., Singh, P. P., & Sharma, R. (2024). Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid. Journal of Medicinal Chemistry, 67(4), 2264-2286. https://doi.org/10.1021/acs.jmedchem.3c01892

Vancouver

Negi A, Perveen S, Gupta R, Singh PP, Sharma R. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid. Journal of Medicinal Chemistry. 2024;67(4):2264-2286. doi:10.1021/acs.jmedchem.3c01892

BibTeX
@article{Negi2024,
  author = {Negi, Anjali and Perveen, Summaya and Gupta, Ria and Singh, Parvinder Pal and Sharma, Rashmi},
  title = {Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {4},
  pages = {2264--2286},
  doi = {10.1021/acs.jmedchem.3c01892}
}
Kostenlos starten →